Recombinant Human TGF-β1 Animal Component Free

Catalog Number: ACFP240

DESCRIPTION

Source	*Spodoptera frugiperda*, *Sf* 9 (baculovirus)-derived Ala279-Ser390 Accession # P01137 Produced in an animal component free process (ACFP).
N-terminal Sequence Analysis	Ala279
Structure / Form	Disulfide-linked homodimer
Predicted Molecular Mass	12.8 kDa (monomer)

SPECIFICATIONS

SDS-PAGE	11 kDa, reducing conditions
Activity	Measured by its ability to inhibit the IL-4-dependent proliferation of HT-2 mouse T cells. Tsang, M. *et al.* (1995) Cytokine **7**:389. The ED_{50} for this effect is 0.04-0.2 ng/mL. The specific activity of recombinant human TGF-β1 is approximately 2.5 x 10^4 U/µg, which is calibrated against human TGF-β1 Standard (NIBSC code: 89/514).
Endotoxin Level	<0.10 EU per 1 µg of the protein by the LAL method.
Purity	>95%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.
Formulation	Lyophilized from a 0.2 µm filtered solution in Acetonitrile and TFA. See Certificate of Analysis for details.

PREPARATION AND STORAGE

Reconstitution	Reconstitute at 100 µg/mL in sterile 4 mM HCl.
Shipping	The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage	**Use a manual defrost freezer and avoid repeated freeze-thaw cycles.** ● 12 months from date of receipt, -20 to -70 °C as supplied. ● 1 month, 2 to 8 °C under sterile conditions after reconstitution. ● 3 months, -20 to -70 °C under sterile conditions after reconstitution.

BACKGROUND

TGF-β1 (transforming growth factor beta 1) is one of three closely related mammalian members of the large TGF-β superfamily that share a characteristic cystine knot structure (1-7). TGF-β1, -2 and -3 are highly pleiotropic cytokines that are proposed to act as cellular switches that regulate processes such as immune function, proliferation and epithelial-mesenchymal transition (1-4). Each TGF-β isoform has some non-redundant functions; for TGF-β1, mice with targeted deletion show defects in hematopoiesis and endothelial differentiation, and die of overwhelming inflammation (2). Human TGF-β1 cDNA encodes a 390 amino acid (aa) precursor that contains a 29 aa signal peptide and a 361 aa proprotein (8). A furin-like convertase processes the proprotein to generate an N-terminal 249 aa latency-associated peptide (LAP) and a C-terminal 112 aa mature TGF-β1 (8, 9). Disulfide-linked homodimers of LAP and TGF-β1 remain non-covalently associated after secretion, forming the small latent TGF-β1 complex (8-10). Covalent linkage of LAP to one of three latent TGF-β binding proteins (LTBPs) creates a large latent complex that may interact with the extracellular matrix (9, 10). TGF-β is activated from latency by pathways that include actions of the protease plasmin, matrix metalloproteases, thrombospondin 1 and a subset of integrins (10). Mature human TGF-β1 shares 100% aa identity with pig, dog and cow TGF-β1, and 99% aa identity with mouse, rat and horse TGF-β1. It demonstrates cross-species activity (1). TGF-β1 signaling begins with high-affinity binding to a type II ser/thr kinase receptor termed TGF-β RII. This receptor then phosphorylates and activates a second ser/thr kinase receptor, TGF-β RI (also called activin receptor-like kinase (ALK) -5), or alternatively, ALK-1. This complex phosphorylates and activates Smad proteins that regulate transcription (3, 11, 12). Contributions of the accessory receptors betaglycan (also known as TGF-β RIII) and endoglin, or use of Smad-independent signaling pathways, allow for disparate actions observed in response to TGF-β in different contexts (11).

References:

1. Derynck, R. and K. Miyazono (2008) Cold Spring Harbor Laboratory Press, 29.
2. Dunker, N. and K. Krieglstein (2000) Eur. J. Biochem. **267**:6982.
3. Wahl, S.M. (2006) Immunol. Rev. **213**:213.
4. Chang, H. *et al.* (2002) Endocr. Rev. **23**:787.
5. Lin, J.S. *et al.* (2006) Reproduction **132**:179.
6. Hinck, A.P. *et al.* (1996) Biochemistry **35**:8517.
7. Mittl, P.R.E. *et al.* (1996) Protein Sci. **5**:1261.
8. Derynck, R. *et al.* (1985) Nature **316**:701.
9. Miyazono, K. *et al.* (1988) J. Biol. Chem. **263**:6407.
10. Oklu, R. and R. Hesketh (2000) Biochem. J. **352**:601.
11. de Caestecker, M. *et al.* (2004) Cytokine Growth Factor Rev. **15**:1.
12. Zuniga, J.E. *et al.* (2005) J. Mol. Biol. **354**:1052.

bio-techne®
Global bio-techne.com info@bio-techne.com techsupport@bio-techne.com TEL +1 612 379 2956
USA TEL 800 343 7475 Canada TEL 855 668 8722 China TEL +86 (21) 52380373
Europe | Middle East | Africa TEL +44 (0)1235 529449

Recombinant Human TGF-β1
Animal Component Free

Catalog Number: ACFP240

MANUFACTURING SPECIFICATIONS

Animal Component-Free Process (ACFP) Manufacturing Conditions

R&D Systems Animal Component-Free Process (ACFP) recombinant proteins are expressed in an animal-free certified *Sf 9* insect cell line using dedicated animal-free raw materials and labware. Production and purification procedures use equipment and media that are confirmed animal-free but performed outside our dedicated animal-free laboratories. Every stage of the manufacturing process follows R&D Systems' stringent Standard Operating Procedures (SOPs). The certified *Sf 9* insect cell bank has undergone extensive testing to certify the lack of cytopathogens by screening for various viruses, Mycoplasma, and Spiroplasmas using both *in vitro* and *in vivo* testing methods. For *ex vivo* research or bioproduction, additional documentation can be provided.

Please read our complete ACFP Statement

bio-techne®
Global bio-techne.com info@bio-techne.com techsupport@bio-techne.com TEL +1 612 379 2956
USA TEL 800 343 7475 **Canada** TEL 855 668 8722 **China** TEL +86 (21) 52380373
Europe | Middle East | Africa TEL +44 (0)1235 529449